Candida Parapsilosis

Dosage for Candida Parapsilosis is highly individualized and must be determined by a physician experienced in allergy management.

Diagnostic Skin Testing:

• Prick/Puncture Test: Usually performed with a concentrated glycerinated extract (e.g., 1:10 or 1:20 w/v). A single drop is applied to the skin, and a sterile lancet is used to prick the epidermis.
• Intradermal Test: If the prick test is negative, an intradermal test may be performed using a much more dilute aqueous solution (e.g., 0.02 mL of a 1:1000 or 1:500 w/v concentration).

Immunotherapy (Desensitization):

• Build-up Phase: Treatment starts with a very low dose (e.g., 0.05 mL of a 1:100,000 w/v dilution). Injections are typically given once or twice weekly, with the dose increasing by 50% to 100% each time, provided no significant local or systemic reactions occur.
• Maintenance Phase: Once the 'maintenance dose' is reached (the highest dose tolerated by the patient that provides symptomatic relief, often 0.5 mL of a 1:100 or 1:10 w/v concentration), the interval between injections is increased to every 2 to 4 weeks.

Candida Parapsilosis is used in children, but the dosage must be approached with extreme caution. The volume of the injection is generally the same as in adults, but the starting concentration may be further diluted depending on the child's sensitivity level. Pediatric patients are at a higher risk for systemic reactions, and the decision to initiate immunotherapy should be based on the severity of the allergy and the child's ability to cooperate with the treatment regimen.

Renal Impairment

No specific dosage adjustments are typically required for renal impairment, as the extract is not cleared through the kidneys in a way that would lead to toxic accumulation of a parent drug. However, the patient's overall health must be considered.

Hepatic Impairment

No dosage adjustments are required for hepatic impairment.

Elderly Patients

Elderly patients may have a diminished skin response to allergens. Care must be taken when interpreting diagnostic tests. Furthermore, older patients are more likely to have underlying cardiovascular disease, which increases the risk of complications if a systemic reaction (anaphylaxis) occurs.

Candida Parapsilosis is administered exclusively by healthcare professionals in a clinical setting equipped to handle emergency reactions.

• Skin Testing: Usually performed on the volar surface of the forearm or the upper back. The skin must be clean and free of topical steroids.
• Immunotherapy: Administered via deep subcutaneous injection, typically in the posterior aspect of the upper arm. The site should be rotated between the left and right arms.
• Storage: Vials must be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). They must not be frozen. Potency decreases over time, especially in highly diluted vials.

In immunotherapy, a missed dose can lead to a loss of tolerance. If a dose is missed by more than a week during the build-up phase, the physician may need to repeat the previous dose or even reduce the dose to ensure safety. If missed during the maintenance phase, the schedule must be adjusted based on the length of the delay.

An 'overdose' in the context of allergenic extracts usually refers to the administration of a dose higher than the patient's current tolerance level.

• Signs: Rapid onset of hives (urticaria), swelling (angioedema), wheezing, shortness of breath, drop in blood pressure, or loss of consciousness.
• Emergency Measures: Immediate administration of epinephrine (1:1000) intramuscularly, followed by oxygen, IV fluids, and antihistamines. Patients must be monitored for at least 30 minutes after every injection.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or attempt to self-administer these injections without medical guidance.

Most patients receiving Candida Parapsilosis for diagnostic testing or immunotherapy will experience local reactions.

• Local Wheal and Flare: During skin testing, a red, itchy bump is the expected result in sensitized individuals. This typically peaks within 15-20 minutes and resolves within an hour.
• Injection Site Swelling: In immunotherapy, swelling at the site of injection is very common. This may feel like a firm knot under the skin and can be slightly tender. It usually lasts 24 to 48 hours.
• Pruritus (Itching): Localized itching at the injection site is frequent and can be managed with cool compresses.

• Large Local Reactions (LLR): Swelling that exceeds 5-10 cm in diameter at the injection site. This may indicate that the next dose should not be increased.
• Fatigue: Some patients report feeling unusually tired for several hours following an immunotherapy injection.
• Headache: Mild tension-type headaches have been reported following administration.

• Systemic Urticaria: Hives appearing on parts of the body distant from the injection site.
• Delayed Reactions: Swelling or redness that appears 6 to 24 hours after the injection. While usually not dangerous, these should be reported to the doctor.
• Lymphadenopathy: Swelling of the lymph nodes near the injection site (e.g., in the armpit).

> Warning: Stop taking Candida Parapsilosis and call your doctor immediately if you experience any of these symptoms of anaphylaxis.

• Respiratory Distress: Difficulty breathing, tightness in the chest, or a high-pitched gasping sound (stridor).
• Angioedema: Significant swelling of the lips, tongue, or throat that may interfere with swallowing or breathing.
• Hypotension: A sudden drop in blood pressure, which may feel like extreme dizziness, lightheadedness, or 'seeing stars.'
• Tachycardia: A rapid or pounding heartbeat.
• Syncope: Fainting or loss of consciousness.
• Generalized Seizures: Rare, but can occur in the context of severe systemic shock.

There are no known long-term 'toxic' effects of Candida Parapsilosis extract, as it is a biological product. However, the primary long-term risk is the development of new sensitivities (though rare) or the persistence of local site reactions that may cause minor skin thickening over years of treatment. The benefit of long-term immunotherapy is the potential for permanent reduction in allergy symptoms.

While Candida Parapsilosis specifically may not have a unique black box warning, the entire class of Allergenic Extracts carries a general warning regarding the risk of severe non-fatal and fatal systemic reactions.

Summary of Warning:

1. 1Allergenic extracts can cause severe life-threatening systemic reactions, including anaphylaxis.
2. 2Injections should only be administered in a setting where emergency equipment and trained personnel are available.
3. 3Patients with unstable asthma are at a higher risk for fatal reactions.
4. 4Patients taking beta-blockers may be resistant to the effects of epinephrine used to treat anaphylaxis.

Report any unusual symptoms to your healthcare provider. Even a 'mild' reaction like an itchy throat or sneezing after an injection can be a warning sign of a more severe reaction to follow.

Candida Parapsilosis must be used with extreme caution. Because it is a non-standardized extract, the biological activity is not precisely quantified, making the risk of unexpected reactions higher than with standardized extracts. Patients must remain in the doctor's office for at least 30 minutes after any injection to monitor for systemic reactions.

No specific FDA black box warning exists for the brand name 'Candida Parapsilosis' alone, but the FDA-mandated labeling for all allergenic extracts emphasizes the risk of anaphylaxis. According to the FDA-approved class labeling, these products are intended for use only by physicians who are experienced in the administration of allergenic extracts and the management of anaphylaxis.

• Anaphylaxis Risk: This is the most significant risk. Patients must be screened for recent illness, changes in medication, or increased asthma symptoms before every injection, as these factors can lower the threshold for a systemic reaction.
• Asthma Status: Patients with poorly controlled or unstable asthma should not receive Candida Parapsilosis injections. A flare-up of asthma can make a systemic reaction much more difficult to treat and significantly increases the risk of fatality.
• Beta-Blocker Use: Patients taking beta-blockers (e.g., metoprolol, propranolol) are at increased risk because these drugs block the receptors that epinephrine acts upon. If a patient on a beta-blocker has anaphylaxis, standard doses of epinephrine may be ineffective.
• Injection Technique: Inadvertent intravenous injection can cause an immediate, severe systemic reaction. The healthcare provider must always aspirate the syringe before injecting to ensure the needle is not in a blood vessel.

There are no routine lab tests (like blood counts or liver enzymes) required for Candida Parapsilosis. However, clinical monitoring is intensive:

• Pre-injection assessment: Check for current allergy symptoms and peak flow (for asthmatics).
• Post-injection observation: 30-minute mandatory wait time.
• Site assessment: The previous injection site must be checked for large local reactions before the next dose is given.

Candida Parapsilosis generally does not affect the ability to drive. However, if a patient experiences a systemic reaction or receives epinephrine, they should not drive until they are fully recovered and cleared by a physician.

There is no direct chemical interaction between alcohol and Candida Parapsilosis. However, alcohol consumption can cause vasodilation and may theoretically increase the rate of absorption of the allergen or mask the early symptoms of a systemic reaction. It is generally advised to avoid alcohol for several hours after an injection.

Immunotherapy can be discontinued at any time, but the benefits of desensitization will gradually be lost. There is no 'withdrawal' syndrome associated with stopping allergenic extracts. However, if treatment is paused for an extended period and then restarted, the dose must be significantly reduced to avoid a reaction.

> Important: Discuss all your medical conditions with your healthcare provider before starting Candida Parapsilosis.

• Beta-Adrenergic Blockers: While not an absolute contraindication in all cases, the use of beta-blockers (e.g., atenolol, carvedilol) with allergenic extracts is highly discouraged. The clinical consequence is that the patient may be unresponsive to epinephrine, the primary treatment for life-threatening anaphylaxis. This combination significantly increases the risk of a fatal outcome during a reaction.

• ACE Inhibitors: Some studies suggest that patients taking ACE inhibitors (e.g., lisinopril, enalapril) may be at higher risk for more severe systemic reactions to allergenic extracts, possibly due to the inhibition of bradykinin breakdown.
• Tricyclic Antidepressants (TCAs) and MAOIs: These medications (e.g., amitriptyline, selegiline) can potentiate the effects of epinephrine, leading to severe hypertension or cardiac arrhythmias if epinephrine is required to treat a reaction.

• Antihistamines: Drugs like loratadine (Claritin), cetirizine (Zyrtec), and diphenhydramine (Benadryl) will suppress the skin's response to the allergen. This leads to false-negative results during diagnostic skin testing. Patients must typically stop antihistamines for 3 to 7 days before testing.
• Systemic Corticosteroids: Long-term use of high-dose steroids may suppress the immune response, potentially reducing the efficacy of immunotherapy or masking skin test results.
• H2 Blockers: Medications like famotidine (Pepcid) can also slightly suppress skin test reactions and should be discontinued before diagnostic procedures.

There are no known direct food interactions with Candida Parapsilosis. However, patients should avoid heavy meals or vigorous exercise immediately before and after an injection, as increased body temperature and blood flow can accelerate the absorption of the allergen.

• St. John's Wort: May theoretically interact with medications used to treat anaphylaxis.
• Herbal Antihistamines: Supplements like stinging nettle or butterbur may interfere with skin testing in the same way as pharmaceutical antihistamines.

Candida Parapsilosis does not typically interfere with standard blood chemistry or hematology tests. However, it will directly affect:

• Skin Prick Tests: As intended, it causes a wheal and flare.
• In Vitro Allergy Tests (sIgE): Immunotherapy will eventually lead to changes in serum IgE and IgG4 levels for Candida, which is an expected pharmacological effect rather than an 'interference.'

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.

Candida Parapsilosis must NEVER be used in the following circumstances:

• Previous Severe Systemic Reaction: If a patient has previously experienced life-threatening anaphylaxis to Candida parapsilosis extract, the risk of further treatment usually outweighs the benefits.
• Unstable or Severe Asthma: Patients with an FEV1 (Forced Expiratory Volume) consistently below 70% of predicted or those with recent acute exacerbations are at an unacceptably high risk for fatal bronchospasm during a reaction.
• Acute Infection: Injections should not be given during an active febrile illness, as the immune system is already stressed, and a reaction may be more severe.
• Recent Myocardial Infarction: Patients with unstable angina or recent heart attack should not receive this extract, as they cannot tolerate the cardiovascular stress of anaphylaxis or the side effects of epinephrine.

Conditions requiring careful risk-benefit analysis include:

• Autoimmune Disorders: There is a theoretical risk that immunotherapy could exacerbate underlying autoimmune conditions like lupus or rheumatoid arthritis.
• Malignancy: Patients with active cancer may have altered immune responses.
• Severe Atopic Dermatitis: If the skin is too inflamed, diagnostic skin testing may be impossible or inaccurate.

Patients allergic to Candida parapsilosis may show cross-reactivity with other Candida species (such as Candida albicans) or other yeasts (such as Saccharomyces cerevisiae). This is due to shared protein structures among fungi. If a patient is known to be extremely sensitive to one fungal extract, the physician should assume a high degree of sensitivity to related extracts.

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Candida Parapsilosis.

Candida Parapsilosis is classified as Pregnancy Category C. This means that animal reproduction studies have not been conducted, and it is not known whether the extract can cause fetal harm.

• Risk Summary: The primary risk during pregnancy is not the extract itself, but the potential for maternal anaphylaxis, which can cause fetal hypoxia (lack of oxygen).
• Clinical Practice: Immunotherapy is generally not initiated during pregnancy. However, if a woman is already on a stable maintenance dose and is tolerating it well, the physician may choose to continue the treatment at the same or a slightly reduced dose. Dosage increases should be avoided during pregnancy.

It is not known whether the components of Candida Parapsilosis extract are excreted in human milk. Because the extract consists of large proteins that are likely digested in the infant's gastrointestinal tract, the risk to a nursing infant is considered very low. The decision to continue immunotherapy while breastfeeding should be made based on the mother's clinical need.

Safety and effectiveness in children under the age of 5 have not been well-established, largely due to the difficulty of performing skin tests and the risk of systemic reactions in very young children. For older children, Candida Parapsilosis is used similarly to adults, but with closer monitoring. Growth effects have not been reported with allergenic extracts.

Clinical studies of Candida Parapsilosis did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently than younger subjects. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of concomitant cardiovascular disease and the use of medications like beta-blockers or ACE inhibitors.

There are no specific guidelines for the use of Candida Parapsilosis in patients with renal impairment. Since the proteins are metabolized proteolytically, renal clearance of the parent 'drug' is not a primary concern. However, patients on dialysis may have altered immune status.

No dosage adjustments are necessary for patients with hepatic impairment, as the liver does not play a primary role in the clearance of fungal allergenic proteins.

> Important: Special populations require individualized medical assessment and a cautious approach to immunotherapy.

Candida Parapsilosis extract acts as an exogenous antigen. In the diagnostic setting, it interacts with pre-sensitized IgE antibodies on mast cells. In the therapeutic setting, it acts as an immunomodulator. It targets the T-cell receptor (TCR) on naive T-cells when presented by dendritic cells. This interaction, in the presence of specific cytokines, promotes the differentiation of T-regulatory (Treg) cells. These Tregs produce IL-10 and TGF-beta, which suppress the Th2 allergic response and signal B-cells to switch production from IgE to IgG4.

• Dose-Response: There is a clear dose-response relationship in skin testing; higher concentrations produce larger wheals. In immunotherapy, higher doses generally lead to greater immunological tolerance, but also a higher risk of systemic reactions.
• Onset of Effect: Skin test reactions appear within 15-20 minutes. The therapeutic effects of immunotherapy take much longer, often requiring 3 to 6 months of build-up before a reduction in symptoms is noted.
• Duration of Effect: A skin test is transient. The effects of a full course of immunotherapy (3-5 years) can last for several years after discontinuation.

| Parameter | Value |

|---|---|

| Bioavailability | N/A (Subcutaneous/Intradermal) |

| Protein Binding | Primarily interacts with IgE/IgG |

| Half-life | Hours (proteins) / Months (immune effect) |

| Tmax | 15-20 minutes (skin reaction) |

| Metabolism | Proteolytic degradation |

| Excretion | Renal (metabolites) |

• Composition: A complex mixture of proteins (including enzymes like proteases), glycoproteins, and polysaccharides derived from Candida parapsilosis mycelia and spores.
• Solubility: Soluble in aqueous buffers (e.g., phosphate-buffered saline).
• Molecular Weight: Ranges from 10 kDa to over 100 kDa for various fungal allergens.

Candida Parapsilosis is a Non-Standardized Fungal Allergenic Extract. It is related to other fungal extracts like Aspergillus fumigatus, Alternaria alternata, and Cladosporium herbarum. It is distinct from 'Standardized' extracts like Grass Pollen or Dust Mite, which have federally mandated potency requirements.